Piper Sandler reaffirmed its positive stance on Inspire Medical Systems (NYSE:NYSE:INSP), maintaining an Overweight rating with a $260.00 price target. The endorsement comes after a steep 14.15% ...

Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inspire Medical Systems (INSP – Research ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

Inspire Institute of Sport (IIS), on Sunday, announced a first-of-its-kind International Wrestling Camp for Women, in collaboration with United World Wrestling (UWW). The IIS UWW International Women’s ...

It's official: 2024 is in the books and all eyes are on what this year will bring. Below, I'll break down why this particular exchange-traded fund (ETF) is poised to be a big winner in 2025 and ...

For over 20 years, I have relied on a CPAP machine to manage my sleep apnea—a life-threatening condition that, if left untreated, can cause serious complications, including death during sleep.

Insomnia often causes excessive daytime sleepiness and fatigue. Obstructive sleep apnea (OSA) is when you briefly stop breathing during sleep because the airways of your throat become too narrow ...

The Tennessee Titans have achieved true betting infamy this NFL season. At 2-14 against the spread, the Titans currently have the worst against the spread record of any team in the Super Bowl era ...

So, you can control the volume and launch channels hands-free instead of using your remote. The 50-inch model is down to $329, thanks to today's 31% discount. Mackenzie Frazier is the deals editor ...

More apps? For this social-media reporter, the answer is "always." I'm back with my favorite apps from the year. At a glance, the dozens of apps I've downloaded this year fall into a few themes ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.